Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 3.29

(-4.76%)

Total Assets Summary of Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.'s latest annual total assets in 2024 was 340.79 Million USD , down -6.36% from previous year.
Xeris Biopharma Holdings, Inc.'s latest quarterly total assets in 2024 FY was 340.79 Million USD , down -1.08% from previous quarter.
Xeris Biopharma Holdings, Inc. reported annual total assets of 344.52 Million USD in 2023, down 0.0% from previous year.
Xeris Biopharma Holdings, Inc. reported annual total assets of 344.52 Million USD in 2022, up 13.2% from previous year.
Xeris Biopharma Holdings, Inc. reported quarterly total assets of 340.79 Million USD for 2024 Q2, up 3.97% from previous quarter.
Xeris Biopharma Holdings, Inc. reported quarterly total assets of 340.79 Million USD for 2024 FY, down -1.08% from previous quarter.

Annual Total Assets Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual Total Assets of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year	Total Assets	Total Assets Growth
2024	340.79 Million USD	-6.36%
2023	344.52 Million USD	0.0%
2022	344.52 Million USD	13.2%
2021	304.36 Million USD	91.24%
2020	159.15 Million USD	32.59%
2019	120.02 Million USD	166.74%
2018	44.99 Million USD	34.19%
2017	33.53 Million USD	0.0%

Year	Total Assets	Total Assets Growth
2024 Q3	336.61 Million USD	-1.23%
2024 Q2	340.79 Million USD	3.97%
2024 FY	340.79 Million USD	-1.08%
2024 Q1	327.78 Million USD	-0.3%
2024 Q4	331.73 Million USD	-1.45%
2023 Q3	321.36 Million USD	-2.26%
2023 Q4	328.77 Million USD	2.31%
2023 FY	344.52 Million USD	0.0%
2023 Q1	303.01 Million USD	-4.9%
2023 Q2	328.77 Million USD	8.5%
2022 Q4	318.61 Million USD	-5.63%
2022 FY	344.52 Million USD	13.2%
2022 Q3	337.62 Million USD	10.93%
2022 Q2	304.36 Million USD	131.88%
2022 Q1	131.26 Million USD	-13.36%
2021 Q4	151.49 Million USD	-9.63%
2021 Q1	170.45 Million USD	2.8%
2021 Q2	159.15 Million USD	-6.63%
2021 Q3	167.63 Million USD	5.33%
2021 FY	304.36 Million USD	91.24%
2020 FY	159.15 Million USD	32.59%
2020 Q3	116.46 Million USD	6.86%
2020 Q2	108.98 Million USD	-14.92%
2020 Q1	128.1 Million USD	-4.33%
2020 Q4	165.81 Million USD	42.37%
2019 Q1	137.59 Million USD	-0.48%
2019 FY	120.02 Million USD	166.74%
2019 Q4	133.89 Million USD	-16.82%
2019 Q3	160.97 Million USD	34.11%
2019 Q2	120.02 Million USD	-12.76%
2018 Q2	44.99 Million USD	0.0%
2018 Q4	138.25 Million USD	124.57%
2018 FY	44.99 Million USD	34.19%
2018 Q3	61.56 Million USD	36.81%
2017 Q3	- USD	0.0%
2017 FY	33.53 Million USD	0.0%

Peer Total Assets Comparison of Xeris Biopharma Holdings, Inc.

Name	Total Assets	Total Assets Difference
Arrowhead Pharmaceuticals, Inc.	765.55 Million USD	55.483%
Codexis, Inc.	136.56 Million USD	-149.557%
Viridian Therapeutics, Inc.	490.42 Million USD	30.51%
Organovo Holdings, Inc.	6.34 Million USD	-5267.743%